Pharmacokinetics of ertapenem in healthy young volunteers

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3506-3511

  Majumdar, A K ^a   Musson, D G ^a   Birk, K L ^a   Kitchen, C J ^a   Holland, S ^a   McCrea, J ^a   Mistry, G ^a   Hesney, M ^a   Xi, L ^a   Li, S X ^a   Haesen, R ^a   Blum, R A ^a   Lins, R L ^a   Greenberg, H ^a   Waldman, S ^a   Deutsch, P ^a   Rogers, J D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; ERTAPENEM;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; INFECTION; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BETA-LACTAMS; BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LACTAMS; MALE; PROTEIN BINDING; SEX CHARACTERISTICS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0036841274     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3506-3511.2002     Document Type: Article

References (8)

1. Gill, C. J., J. J. Jackson, L. S. Gerckens, B. A. Pelak, R. K. Thompson, J. G. Sundelof, H. Kropp, and H. Rosen. 1998. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-0826 (L-749345). Antimicrob. Agents Chemother. 42:1996-2001.
2. Gough, K., M. Hutchinson, O. Keene, B. Byron, S. Ellis, L. Lacey, and J. McKellar. 1995. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetic joint working party. Drug Inform. J. 29:1039-1048.
3. Graham, D. R., C. Lucasti, O. Malafaia, R. L. Nichols, P. Holtom, N. Qunitero Perez, A. McAdams, G. L. Woods, T. P. Ceesay, R. Gesser, and the Ertapenem CSSSI Study Group. 2002. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin. Infect. Dis. 34:1460-1468.
4. Musson, D. G. K. L. Birk, A. M. Cairns, A. K. Majumdar, and J. D. Rogers. 1998. High performance liquid chromatographic methods for the determination of a new carbapenem antibiotic, L-749345, in human plasma and urine. J. Chromatogr. B 720:99-106.
5. Ortiz-Ruiz, G., J. Caballero-Lopez, I. R. Friedland, G. L. Woods, A. Carides, and the Ertapenem Community Acquired Pneumonia in Adults. 2002. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone in the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis. 34:1076-1083.
6. Popick, A. C., W. G. Crouthamel, and L. Bekersky. 1987. Plasma protein binding of ceftriaxone. Xenobiotica 17:1139-1145.
7. Stoeckel, K., P. J. McNamara, R. Brandt, H. Plozza-Nottebrock, and W. Ziegler. 1981. Effect of concentration-dependent plasma protein binding on ceftriaxone kinetics, Clin. Pharmacol. Ther. 29:650-657.
8. Wong, B. K., P. J. Bruhin, and J. H. Lin. 1999. Dose-dependent plasma clearance of MK-0826, a carbapenem antibiotic, arising from concentration dependent plasma protein binding in rats and monkeys. J. Pharm. Sci. 88:277-280.